Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin

Cardiovascular Diabetology

Correction

Saki Yamamoto¹  Masako Tomoyasu¹  Makoto Ohara¹  Noriko Nakanishi¹  Takeshi Yamamoto¹  Anna Osamura¹  Tsutomu Hirano¹  Toshiyuki Hayashi¹  Tomoyasu Fukui¹  Yasuki Ito² 

[1] Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, 142-8666, Tokyo, Japan;Reagent R&D Department, Denka Seiken Co., Ltd., Nihonbashi Mitsui Tower, 1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku, 103-8338, Tokyo, Japan;

关键词: ;   

DOI  :  10.1186/s12933-017-0608-5

 received in 2017-10-03, accepted in 2017-10-03,  发布年份 2017

来源: Springer

【 摘 要 】

Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decreased LDL-C group was 0.38±0.10.

【 授权许可】

CC BY   
© The Author(s) 2017